Trial Profile

A FACTOR IX (FIX) GENE TRANSFER, MULTI CENTER EVALUATION OF THE LONG TERM SAFETY AND EFFICACY STUDY OF PF 06838435 AND A DOSE ESCALATION SUBSTUDY IN INDIVIDUALS WITH HEMOPHILIA B

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 27 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fidanacogene-elaparvovec (Primary)
Indications Haemophilia B
Focus Adverse reactions
Sponsors Pfizer

Most Recent Events

24 Feb 2026 Planned End Date changed from 8 Jun 2029 to 25 Oct 2029.
24 Feb 2026 Planned primary completion date changed from 8 Jun 2029 to 29 May 2029.
23 Apr 2025 Planned End Date changed from 6 Jun 2029 to 8 Jun 2029.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com